{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=TMZ&page=10",
    "query": {
      "intervention": "TMZ",
      "page": 10
    },
    "page_size": 10
  },
  "pagination": {
    "page": 10,
    "page_size": 10,
    "total_count": 469,
    "total_pages": 47,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=TMZ&page=11&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=TMZ&page=9&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-19T06:07:31.152Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07708961",
      "title": "Temozolomide, With or Without WSD0922-FU, for the Treatment of EGFR-Mutant, IDH-Wildtype Glioblastoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Glioblastoma, IDH-Wildtype"
      ],
      "interventions": [
        {
          "name": "Archive Sample Retrieval",
          "type": "PROCEDURE"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Chest Radiography",
          "type": "PROCEDURE"
        },
        {
          "name": "Echocardiography Test",
          "type": "PROCEDURE"
        },
        {
          "name": "EGFR/EGFRvIII Inhibitor WSD0922-FU",
          "type": "DRUG"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Temozolomide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2026-08-28",
      "completion_date": "2036-08-31",
      "has_results": false,
      "last_update_posted_date": "2026-10-15",
      "last_synced_at": "2026-10-19T06:07:31.152Z",
      "location_count": 3,
      "location_summary": "Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07708961"
    },
    {
      "nct_id": "NCT00262730",
      "title": "Radiation Therapy and Temozolomide Followed by Temozolomide and Poly ICLC in Treating Patients With Newly Diagnosed GBM",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Glioblastoma Multiforme"
      ],
      "interventions": [
        {
          "name": "poly ICLC",
          "type": "DRUG"
        },
        {
          "name": "temozolomide",
          "type": "DRUG"
        },
        {
          "name": "radiation therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 97,
      "start_date": "2006-01",
      "completion_date": "2010-04",
      "has_results": true,
      "last_update_posted_date": "2019-06-12",
      "last_synced_at": "2026-10-19T06:07:31.152Z",
      "location_count": 9,
      "location_summary": "Birmingham, Alabama • Tampa, Florida • Atlanta, Georgia + 6 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00262730"
    },
    {
      "nct_id": "NCT02446704",
      "title": "Study of Olaparib and Temozolomide in Patients With Recurrent Small Cell Lung Cancer Following Failure of Prior Chemotherapy",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Olaparib",
          "type": "DRUG"
        },
        {
          "name": "Temozolomide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Zofia Piotrowska",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 66,
      "start_date": "2015-10-13",
      "completion_date": "2023-12",
      "has_results": false,
      "last_update_posted_date": "2022-02-07",
      "last_synced_at": "2026-10-19T06:07:31.152Z",
      "location_count": 3,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02446704"
    },
    {
      "nct_id": "NCT00611247",
      "title": "Phase 2 Study of Temozolomide to Treat Poor Risk / Refractory Acute Myeloid Leukemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Leukemia, Myeloid"
      ],
      "interventions": [
        {
          "name": "Temozolomide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bruno C. Medeiros",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "60 Years and older"
      },
      "enrollment_count": 42,
      "start_date": "2007-12",
      "completion_date": "2010-01",
      "has_results": true,
      "last_update_posted_date": "2018-06-15",
      "last_synced_at": "2026-10-19T06:07:31.152Z",
      "location_count": 1,
      "location_summary": "Stanford, California",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00611247"
    },
    {
      "nct_id": "NCT00004259",
      "title": "Radiation Therapy Combined With Chemotherapy in Treating Patients With Anaplastic Astrocytoma or Mixed Gliomas",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Brain and Central Nervous System Tumors"
      ],
      "interventions": [
        {
          "name": "BCNU 80mg/m2",
          "type": "DRUG"
        },
        {
          "name": "TMZ 200mg/m2",
          "type": "DRUG"
        },
        {
          "name": "radiation therapy",
          "type": "RADIATION"
        },
        {
          "name": "CCNU",
          "type": "DRUG"
        },
        {
          "name": "BCNU 150mg/m2",
          "type": "DRUG"
        },
        {
          "name": "BCNU 200mg/m2",
          "type": "DRUG"
        },
        {
          "name": "TMZ 150mg/m2 six 6-week cycles",
          "type": "DRUG"
        },
        {
          "name": "TMZ 150mg/m2 six 8-week cycles",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Radiation Therapy Oncology Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 230,
      "start_date": "2000-06",
      "completion_date": "2018-05-14",
      "has_results": true,
      "last_update_posted_date": "2019-09-12",
      "last_synced_at": "2026-10-19T06:07:31.152Z",
      "location_count": 92,
      "location_summary": "Mobile, Alabama • Phoenix, Arizona • Chico, California + 71 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Chico",
          "state": "California"
        },
        {
          "city": "Fairfield",
          "state": "California"
        },
        {
          "city": "Vacaville",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00004259"
    },
    {
      "nct_id": "NCT00591370",
      "title": "Phase II Trial of Extended-Dosing Temozolomide in Patients With Melanoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Melanoma"
      ],
      "interventions": [
        {
          "name": "Temozolomide (TMZ)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "16 Years and older"
      },
      "enrollment_count": 51,
      "start_date": "2005-01",
      "completion_date": "2008-06",
      "has_results": true,
      "last_update_posted_date": "2023-07-25",
      "last_synced_at": "2026-10-19T06:07:31.152Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00591370"
    },
    {
      "nct_id": "NCT02366728",
      "title": "DC Migration Study for Newly-Diagnosed GBM",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Glioblastoma",
        "Astrocytoma, Grade IV",
        "Giant Cell Glioblastoma",
        "Glioblastoma Multiforme"
      ],
      "interventions": [
        {
          "name": "Unpulsed DCs",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Td",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Human CMV pp65-LAMP mRNA-pulsed autologous DCs",
          "type": "BIOLOGICAL"
        },
        {
          "name": "111In-labeled DCs",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Temozolomide",
          "type": "DRUG"
        },
        {
          "name": "Saline",
          "type": "DRUG"
        },
        {
          "name": "Basiliximab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Mustafa Khasraw, MBChB, MD, FRCP, FRACP",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 64,
      "start_date": "2015-10-12",
      "completion_date": "2020-10-31",
      "has_results": true,
      "last_update_posted_date": "2023-06-08",
      "last_synced_at": "2026-10-19T06:07:31.152Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02366728"
    },
    {
      "nct_id": "NCT03782415",
      "title": "Study to Evaluate Ibudilast and TMZ Combo Treatment in Newly Diagnosed and Recurrent Glioblastoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Glioblastoma",
        "Recurrent Glioblastoma",
        "GBM",
        "Newly Diagnosed Glioblastoma"
      ],
      "interventions": [
        {
          "name": "MN-166",
          "type": "DRUG"
        },
        {
          "name": "Temozolomide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "MediciNova",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 64,
      "start_date": "2018-12-29",
      "completion_date": "2023-08-07",
      "has_results": false,
      "last_update_posted_date": "2025-05-21",
      "last_synced_at": "2026-10-19T06:07:31.152Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03782415"
    },
    {
      "nct_id": "NCT04541407",
      "title": "Temodar Plus Tyrosine Kinase Inhibitors for Progressive CNS Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Non Small Cell Lung Cancer",
        "CNS Progression"
      ],
      "interventions": [
        {
          "name": "Temozolomide plus Osimertinib",
          "type": "DRUG"
        },
        {
          "name": "Temozolomide plus Lorlatinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Colorado, Denver",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1,
      "start_date": "2020-10-29",
      "completion_date": "2022-06-07",
      "has_results": false,
      "last_update_posted_date": "2023-05-16",
      "last_synced_at": "2026-10-19T06:07:31.152Z",
      "location_count": 1,
      "location_summary": "Aurora, Colorado",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04541407"
    },
    {
      "nct_id": "NCT00597493",
      "title": "Ph. 2 Sorafenib + Protracted Temozolomide in Recurrent GBM",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Glioblastoma Multiforme"
      ],
      "interventions": [
        {
          "name": "Sorafenib and Temozolomide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Duke University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 32,
      "start_date": "2007-09",
      "completion_date": "2010-12",
      "has_results": true,
      "last_update_posted_date": "2013-06-24",
      "last_synced_at": "2026-10-19T06:07:31.152Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00597493"
    }
  ]
}